Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Authors:

Top Cited Papers
Open Access
Abstract
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.
All Related Versions
Funding Information
  • National Institute of Allergy and Infectious Diseases (R37AI64003)
  • National Institute of Allergy and Infectious Diseases (R01AI078788)
  • National Institute of Allergy and Infectious Diseases (P01AI138398-S1)
  • National Institute of Allergy and Infectious Diseases (R01AI091707-10S1)
  • George Mason University (Fast Grant)
  • European ATAC Consortium (EC101003650)
  • National Institutes of Health (UL1 TR001866)
  • National Institute of Allergy and Infectious Diseases (2U19AI111825)
  • G. Harold and Leila Y. Mathers Charitable Foundation
  • Robert S. Wennett Post-Doctoral Fellowship
  • Shapiro-Silverberg Fund (Advancement of Translational Research)
  • Howard Hughes Medical Institute (Investigators)
  • National Institute of General Medical Sciences (T32GM007739)

This publication has 49 references indexed in Scilit: